Seeking Alpha

Galena Biopharma (GALE) +11.7% premarket on news of the issuance of a key patent covering the...

Galena Biopharma (GALE) +11.7% premarket on news of the issuance of a key patent covering the use of its NeuVax product candidate for breast cancer patients having low-to-intermediate IHC levels, which represent a significant unmet medical need with as much as 80% of patients who do not qualify for Herceptin therapy.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs